Literature DB >> 34976284

Photodynamic Therapy for Actinic Keratoses of the Upper Extremities using 10% Aminolevulinic Acid Gel, Red Light, and Adapalene Pretreatment.

Barry I Galitzer1.   

Abstract

BACKGROUND: Actinic keratoses (AKs) are sun-induced cutaneous lesions that may progress to squamous cell carcinoma (SCC). Photodynamic therapy (PDT) is an ideal treatment option for AKs because it allows for treatment of field cancerization, selective destruction of diseased tissue, good cosmetic outcomes, and limited downtime.
OBJECTIVES: This study sought to determine the efficacy and safety of pretreating AKs of the dorsal hands and forearms with adapalene gel, an inexpensive and over-the-counter retinoid, prior to debridement of the target area and PDT with aminolevulinic hydrochloride acid (ALA, 10%) gel and narrowband red light.
METHODS: Fifteen patients with AK lesions of the right or left dorsal hands or forearms were pretreated with adapalene gel (0.1%) twice daily for one week prior to ALA-PDT. The other hand or forearm was treated with ALA-PDT (standard therapy), but not pretreated. For PDT, all treated areas were debrided with sandpaper, degreased with acetone, incubated for one hour with 10% ALA gel under occlusion, and illuminated with narrowband red light (~635 nm). All patients experienced one PDT treatment session.
RESULTS: Eight weeks after treatment, 12 subjects in the adapalene-pretreated group achieved 50% to 100% clearance compared to 10 subjects in the standard therapy group. The median lesion count reduction in the adapalene-pretreated group was -79% compared to -57% in the standard therapy group, and this difference was significant (P=0.0164). The treatment was well-tolerated and the level of patient satisfaction was high.
CONCLUSIONS: Pretreatment with adapalene gel twice daily for one week may enhance efficacy in a single ALA-PDT treatment of AK lesions of the dorsal hand or forearm.
Copyright © 2021. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Cutaneous lesions; field cancerization; lesion count; photosensitizing agent; protoporphyrin

Year:  2021        PMID: 34976284      PMCID: PMC8711616     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  20 in total

Review 1.  The importance of treating the field in actinic keratosis.

Authors:  E Stockfleth
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03       Impact factor: 6.166

2.  Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.

Authors:  Michael Shaffelburg
Journal:  J Drugs Dermatol       Date:  2009-01       Impact factor: 2.114

Review 3.  Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis.

Authors:  John E Wolf; Darrell S Rigel
Journal:  Int J Dermatol       Date:  2013-09       Impact factor: 2.736

4.  Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate.

Authors:  Christine B Warren; Sara Lohser; Lauren C Wene; Brian W Pogue; Philip L Bailin; Edward V Maytin
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

5.  5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial.

Authors:  Edward V Maytin; Sanjay Anand; Margo Riha; Sara Lohser; Alejandra Tellez; Rim Ishak; Lauren Karpinski; Janine Sot; Bo Hu; Anton Denisyuk; Scott C Davis; Angela Kyei; Allison Vidimos
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

6.  Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy.

Authors:  Dore J Gilbert
Journal:  J Drugs Dermatol       Date:  2005 Mar-Apr       Impact factor: 2.114

7.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.

Authors:  T Dirschka; P Radny; R Dominicus; H Mensing; H Brüning; L Jenne; L Karl; M Sebastian; C Oster-Schmidt; W Klövekorn; U Reinhold; M Tanner; D Gröne; M Deichmann; M Simon; F Hübinger; G Hofbauer; G Krähn-Senftleben; F Borrosch; K Reich; C Berking; P Wolf; P Lehmann; M Moers-Carpi; H Hönigsmann; K Wernicke-Panten; C Helwig; M Foguet; B Schmitz; H Lübbert; R-M Szeimies
Journal:  Br J Dermatol       Date:  2011-12-21       Impact factor: 9.302

8.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.

Authors:  R-M Szeimies; P Radny; M Sebastian; F Borrosch; T Dirschka; G Krähn-Senftleben; K Reich; G Pabst; D Voss; M Foguet; R Gahlmann; H Lübbert; U Reinhold
Journal:  Br J Dermatol       Date:  2010-05-28       Impact factor: 9.302

9.  A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage.

Authors:  Dany Touma; Mina Yaar; Sara Whitehead; Nellie Konnikov; Barbara A Gilchrest
Journal:  Arch Dermatol       Date:  2004-01

10.  Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial.

Authors:  Christiane Bay; Catharina Margrethe Lerche; Bradford Ferrick; Peter Alshede Philipsen; Katrine Togsverd-Bo; Merete Haedersdal
Journal:  JAMA Dermatol       Date:  2017-04-01       Impact factor: 10.282

View more
  1 in total

Review 1.  Combination-Based Strategies for the Treatment of Actinic Keratoses with Photodynamic Therapy: An Evidence-Based Review.

Authors:  Stefano Piaserico; Roberto Mazzetto; Emma Sartor; Carlotta Bortoletti
Journal:  Pharmaceutics       Date:  2022-08-18       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.